BLA submitted to FDA for imlifidase in desensitization for kidney transplantation – Hansa Biopharma
Hansa Biopharma AB announced the submission of a Biologics License Application (BLA) to the FDA for imlifidase. The Company is requesting priority review of the BLA for the… read more.

